Catalys Pacific
VC Fund
Fujisawa, Japan
Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences. Founded in 2019, the firm's mission is to focus on providing healthcare solutions for patients worldwide through the creation of and investment in bioventure companies. Catalys Pacific is led by a global team versed in working closelywith its partners in academia, biotech, venture capital and the pharmaceutical industry in Japan and worldwide. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in Seattle, Washington.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 38%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Catalys Pacific invests in
Stages Catalys Pacific invests in
Countries Catalys Pacific invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
BT Slingsby
|
|||
|
Ashwin Ram
|
|||
Ashwin Ram
|
|||
|
Hiromi Miwa
|
|||
|
Maki Haginoya
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Biotechnology 5 (24%)
- Biopharma 4 (19%)
- Pharmaceutical 4 (19%)
- Medical 3 (14%)
- Therapeutics 3 (14%)
Stage
- Series A 6 (29%)
- Seed 4 (19%)
- Series B 3 (14%)
- Private Equity 1 (5%)
- Venture - Series Unknown 1 (5%)
Country
- United States 7 (33%)
- Japan 2 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
BT Slingsby
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 12 | Find email | |
|
Ashwin Ram
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Ashwin Ram
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Hiromi Miwa
Junior Associate
|
Junior Associate | Total investments: 0 | Find email | |
|
Maki Haginoya
Junior Associate
|
Junior Associate | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Crystalys Therapeutics
|
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $205M / Series A / Sep 30, 2025 | |
Pathalys Pharma
|
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $105M / Series B / Aug 20, 2024 | |
Renalys Pharma
|
Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients. | $38.5M / Series A / Jul 17, 2024 | |
Arialys Therapeutics
|
Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment. | $58M / Seed / Sep 12, 2023 | |
|
Pathalys Pharma
|
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $150M / Series A / Jan 18, 2023 | |
Mineralys Therapeutics
|
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $118M / Series B / Jun 08, 2022 | |
|
Mineralys Therapeutics
|
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $118M / Series B / Jun 08, 2022 | |
Aculys Pharma
|
Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients. | $22.9M / Series B / Mar 27, 2022 | |
|
Aculys Pharma
|
Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients. | $22.9M / Series B / Mar 27, 2022 | |
|
Aculys Pharma
|
Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients. | $59.9M / Series A / Oct 28, 2021 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Catalys Pacific invest in?
Catalys Pacific invests primarily in Biotechnology, Biopharma and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Catalys Pacific?
Public channels for Catalys Pacific include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Catalys Pacific?
The team at Catalys Pacific includes BT Slingsby (Founder & Managing Partner), Ashwin Ram (Vice President) and Ashwin Ram (Vice President), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
